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ABSTRACT: 100 words 
We evaluated performance of Abbott PanBio
®
 COVID-19 Rapid Antigen Test Device
(RATD) to detect SARS-CoV-2 infection in adults during high prevalence COVID-19 
outbreaks. We found high accuracy in correct diagnosis (88% CI 85-91%, p<0.05) regardless 
of gender, presence of symptoms, disease timeline. Test sensitivity appeared to increase with 
age, specificity seemed to decline. Best diagnostic accuracy was obtained in middle-aged 
adults (94% CI 89-97%, p<0.05), but remained high through all ages. These results support 
RATD as a reliable measure to determine isolation of infected individuals during outbreaks. 
More studies are needed to assess RATD performance in low prevalence post-vaccination 
scenarios. 
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INTRODUCTION: 114 words 
The coronavirus disease 2019 (COVID-19) pandemic, particularly in the context of 
widespread transmission of new viral variants, has led to an ongoing need for early and 
reliable detection of individuals with acute SARS-CoV-2 infection
1,2,3
, mainly for isolation
purposes
2,4,5,6
. Previous studies have shown different results for several rapid antigen testing
devices using reverse transcription polymerase chain reaction (RT-PCR) as a reference 
method
1,3,7,8,9
, being most efficient in the days around the onset of symptoms
2,4
, or when the
viral load is highest
2,3,5,6
. However, their performance during actual COVID-19 outbreaks in
family practice, including detecting close contacts and asymptomatic individuals, or 
according to gender and age groups, has not yet been documented
5,7,8
.
METHODS: 182 words 
During a serious community COVID-19 outbreak in [redacted], Spain, with exceptionally 
high prevalence (31%) of SARS-Cov-2 infection, we collected nasopharyngeal specimens 
(NPhS) from 380 close contact adults attending Primary HealthCare Centres. NPhS were 
properly taken from the surface of the respiratory mucosa with nasopharyngeal swabs, and 
then analyzed by RATD and RT-PCR assay. Proper NPhS collection meant swabbing both 
nostrils, carefully inserting deep at a horizontal angle between the nasal opening and external 
ear canal. Data from 7 cases were eliminated due to invalid tests or insufficient information. 
This resulted in a final sample of 373 adults (average 56.14 ± 2.06 years old, range: 21-102), 
27,08% (n = 101) men and 72.92% (n = 272) women, with a high proportion of clinically 
asymptomatic or presymptomatic cases (57.9%, n = 216). We compared RATD results versus 
RT-PCR, regardless of their cycle threshold (Ct) values. Sensitivity, specificity and 
diagnostic accuracy, amongst other parameters, were calculated using Fisher’s exact test to 
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analyze corresponding 2x2 contingency tables, and then recalculated by gender and age 
ranges corresponding to young adults, middle-aged adults, older adults, and eldest people. 
RESULTS: 207 words 
In our sample, RATD testing correctly diagnosed 88% (CI 85-91% p<0.05) of cases infected 
by SARS-CoV-2, symptomatic and asymptomatic, regardless of their disease timeline (table 
1). This relates to a high mean sensitivity (79%) and very high mean specificity (93%). 
Diagnostic accuracy seems to be similar for men and women, despite a higher prevalence of 
infection in men (41%) than in women (28%), and a proportionally greater number of women 
in our sample. Sensitivity, likewise, is very similar in men and women, and specificity is 
slightly higher in men than in women, with no significant differences. Considering RATD 
outcomes by age (figure 1), we found a high level of diagnostic accuracy across all age 
groups: 21-40 y.o. 83% (CI 71-90% p<0.05), 41-60 y.o. remarkably 94% (CI 89-97% 
p<0.05), 61-80 y.o. 88% (CI 77-95% P<0.05), and more than 80 y.o. 83% (CI 73-90% 
p<0.05). We observed higher sensitivity with increasing age: 21-40 y.o. 39% (CI 18-64% 
p<0.05, 41-60 y.o. 53% (CI 29-76% p<0.05), 61-80 y.o. 87% (CI 65-97% p<0.05), >80 y.o. 
95% (CI 85-99% p<0.05), and the opposite for specificity, which declines with age: 21-40 
y.o. 98% (CI 88-100% p<0.05), 41-60 y.o. 99% (CI 96-100% p<0.05), 61-80 y.o. 89% (CI
74-96% p<0.05), >80 y.o. 56% (CI 36-74% p<0.05).
DISCUSSION: 258 words 
The current COVID-19 pandemic has revealed the challenges that Family Medicine endures 
to manage high infection outbreaks and the need for efficient, rapid and convenient 
diagnostic tools that include the detection of asymptomatic cases
2,4,7
.
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Amongst its strengths, our study demonstrates the benefits of reliably using RATD testing in 
primary care settings including a faster speed of isolating infective cases. Overall, in high 
prevalence community COVID-19 outbreaks a positive RATD result is likely to indicate a 
truly infected person and may not require additional confirmation by RT-PCR. A negative 
test should be confirmed by RT-PCR where available, or another rapid antigen test a few 
days later
10
. We believe that careful specimen collection is essential to identify a large
number of low viral load cases, thus improving overall epidemic control by reducing 
COVID-19 spread.   
Our study included significant vulnerable and elderly populations, many in nursing homes. 
Whereas local protocols favor the use of RT-PCR to exclude other respiratory illnesses in this 
group
6,10
, our results indicate that RATD could be used instead, with a high level of
confidence. 
Although our findings could contribute to the managing of COVID-19 outbreaks in Family 
Medicine settings, they clearly have inherent limitations. More studies are required to explore 
other areas of interest in detail: correlation of RATD outcomes with RT-PCR Ct, multivariate 
analysis in larger studies to find a logistic regression model considering age, gender, 
multidimensional characteristics of symptoms, and infection timeline, and more importantly, 
RATD diagnostic accuracy in post-vaccination scenarios characterized by low prevalence of 
SARS-CoV-2 infection for the coming years.  
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Table 1.  Diagnostic performance of SARS-CoV-2 RATD during outbreaks, by gender 
Sample / Subgroup Average percent - 95% CI 
All   (N=373) 
Diagnostic accuracy 88   (85-91) 
Sensitivity 79   (70-85) 
Specificity 
Men      (N=101) 






    Specificity 
93  (89-96) 
89  (81-94) 
78   (62-89) 
97   (87-99) 
88   (84-92) 
79   (68-87) 
92  (87-95) 
   N - sample size; CI – confidence interval 
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